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Abstract
We propose an adaptive design for early phase drug combination cancer
trials with the goal of estimating the maximum tolerated dose (MTD). A non-
parametric Bayesian model, using beta priors truncated to the set of partially
ordered dose combinations, is used to describe the probability of dose limiting
toxicity (DLT). Dose allocation between successive cohorts of patients is esti-
mated using a modified Continual Reassessment scheme. The updated proba-
bilities of DLT are calculated with a Gibbs sampler that employs a weighting
mechanism to calibrate the influence of data versus the prior. At the end of
the trial, we recommend one or more dose combinations as the MTD based on
our proposed algorithm. The design operating characteristics indicate that our
method is comparable with existing methods. As an illustration, we apply our
method to a phase I clinical trial of CB-839 and Gemcitabine.
Cancer phase I trials, Drug combination, Maximum tolerated dose, Nonparametric
Bayesian design, Partial ordering.
1 Introduction
The primary objective in conventional phase I clinical trials is to determine the max-
imum tolerated dose (MTD), defined as the dose with the probability of toxicity
closest to a prespecified target. For safety and ethical concerns, most phase I trials
are conducted adaptively, using the dose limiting toxicity (DLT) status of previ-
ously enrolled patients to determine the dose level for the next cohort of patients.
The majority of such trials are designed for single agent, e.g., the conventional 3 +
3 design (Storer, 1989), the continual reassessment method(CRM) and its variants
(O’Quigley et al., 1990), (Goodman et al., 1995), (Korn and Simon, 1991), (Møller,
1995), (O’Quigley and Shen, 1996), (Leung and Wang, 2002), (O’Quigley and Pao-
letti, 2003), (Iasonos and O’Quigley, 2011), (Daimon et al., 2011), (Liu et al., 2013),
the efficient dose escalation with overdose control (EWOC) method and its variants
(Babb et al., 1998; Tighiouart et al., 2014; Tighiouart and Rogatko, 2010; Wheeler
et al., 2017), the modified toxicity probability interval method (Ji and Wang, 2013),
the Bayesian optimal design (Yuan et al., 2016), the nonparametric overdose control
method (Lin and Yin, 2017), the semiparametric dose finding methods (Clertant and
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O’Quigley, 2017) and the Bayesian adaptive design using a flexible range of doses
(Tighiouart et al., 2018).
Recent advances in drug discovery have intensified interest in using dual agents
in phase I clinical trials. This interest is fueled by the fact that drug combinations
may induce a synergistic treatment effect by targeting multiple pathways simulta-
neously and inhibiting resistance mechanisms. A fundamental assumption for cyto-
toxic/biologic agents is monotonicity between toxicity and doses. For single agent,
this assumption induces a complete ordering of the doses. However, in the case of drug
combination treatment where the two agents are allowed to vary, it induces a partial
ordering constraint on the probabilities of toxicities. The monotonicity assumption
coupled with small sample size in phase I clinical trials and higher dimension of the
dose space, make the design of combination trials challenging.
Various model-based designs for drug combinations, have been studied in the
last decade. Thall et al. (2003) proposed a method using a six-parameter model to
define the probability of toxicity as a function of the two doses with the requirement
that each of the two agents had been studied previously as a single agent. Wang
and Ivanova (2005) used a two-stage design with regression model. Yin and Yuan
(2009a) and Yin and Yuan (2009b) developed a design that models the probability
of toxicity with a copula type model. Wages et al. (2011) considered estimation
of toxicity probabilities within a small number of simple orders. Tighiouart et al.
(2017) and Tighiouart et al. (2018) used a reparametrized logistic model to describe
the relationship between the doses of the two agents and the probability of dose
limiting toxicity and extended the work of Tighiouart et al. (2014) by allowing the
MTD curve to lie anywhere in the Cartesian plane of the dose levels of the two drugs
and treating cohorts of two patients simultaneously with different dose combinations.
The method was further extended to account for a baseline covariate by Diniz et al.
(2018) and settings where an unknown fraction of DLTs is attributable to one or
more agents by Jimenez et al. (2019).
In contrast to the parametric models, the nonparametric models do not impose
any functional form on the dose–toxicity relationship. Parametric models suffer from
potential model misspecification, which may lead to unsafe dose escalation. On the
other hand, nonparametric models can capture more subtle aspect of the data, hence
they are more flexible. Several nonparametric models for dual agent clinical trials
have been studied in the past. Lin et al. (2016) estimated the toxicity order of two
drugs by two-dimensional isotonic regression and reduced the two-dimensional drug
combination searching space into a one dimension and used a parametric CRM model
based on the updated toxicity order. Mander and Sweeting (2015) considered a prod-
uct of independent beta probabilities escalation strategy allowing the prior distribu-
tions for each dose combination to be unconstrained and imposing the monotonicity
assumption when escalating by choosing only monotonic contours.
In this paper, we propose a nonparametric Bayesian approach to dose finding for
combinations of drugs (NBCD) by modeling the joint prior probabilities of DLTs
on the space of all dose combinations with independent beta distributions truncated
to the set of combinations that satisfy the partial order. Unlike the PIPE algorithm
proposed by Mander and Sweeting (2015), our approach guarantees that the joint pos-
terior distribution of the probabilities of DLT estimated with Gibbs sampler satisfies
the partial order constraint. A weighted mechanism is introduced when allocating
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doses to successive cohorts of patients in order to calibrate the influence of data and
that of the prior.
The rest of this paper is organized as follows. In Section 3, we propose a nonpara-
metric Bayesian model with beta priors truncated to the set of partially ordered dose
combinations. In Section 4, we present our trial design and an algorithm for dose
recommendation for phase II. We study the performance of our model with extensive
simulations studies in Section 5 and a trial of CB-839 and Gemcitabine in Section 6.
Notation. We use nij and zij to denote the number of patient assigned to the
dose combination dij and the number of DLTs observed at (i, j), respectively. We
use α = (αij) ∈ RK and β = (βij) ∈ RK that collect all αij and βij parameters,
respectively. For any positive integer I, we write [I] = {1, . . . , I}. We denote by p˜ij
and pˆij, the prior and posterior median of the probability of DLT at dose level dij,
respectively.
2 Problem formulation
Consider two drugs A and B with ordered dose levels A = {dAi , i = 1, . . . , I} and
B = {dBj , j = 1, . . . , J}, respectively. Let D = A×B be the set of dose combinations
available in the trial. We denote a typical element of D as dij = (dAi , dBj ). To each
dose combination dij, there is a true probability of toxicity, or DLT, which we denote
as p∗ij. That is,
p∗ij = P
(
Dose combination dij causes a DLT
)
. (1)
Later in our model, we use pij when modeling these probabilities as random.
Given a target probability of DLT θ ∈ (0, 1), we are interested in dose combi-
nations whose p∗ij are close to θ. In order to make this notion precise, we define
δ-approximate MTD as
MTD(δ) := {dij | (i, j) ∈Mδ} (2)
where,
Mδ =
{
(i, j) ∈ [I]× [J ] : |p∗ij − θ| ≤ δ
}
(3)
Our goal is to recover any dose combination in MTD(δ) for prescribed values of
δ and θ. In the sequel, for simplicity, we often say dose combination (i, j) instead of
dij.
2.1 The model
When modeling drug combination trials, we consider the probabilities of DLT as
random variables pij for which we will specify a prior. Let p = (p11, p12, p13, . . . , pIJ)
be the random vector obtained by collecting all the pijs. During the trial, the patients
are assigned to various dose combinations and their toxicity response is recorded.
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Figure 1: Hasse diagram for a 3× 4 lattice
Assume that at a given stage in the trial, we have assigned a total of nij patients to
dose combination (i, j). The number of these patients who experienced DLT, denoted
as zij is distributed as
zij | p ∼ Bin(nij, pij).
Letting N = {(i, j) | nij > 0}, the likelihood of the model is
L(z | p) =
∏
(i,j)∈N
(
nij
zij
)
p
zij
ij (1− pij)nij−zij . (4)
where z = (zij) collects all the zijs. In Section 3.1, we specify a prior for p which
allows to obtain the posterior estimate of p given z = (zij). Given these estimates, we
update our estimate of MTD(δ), assign more patients, and so on. Before specifying
the prior on p, we need to better understand the constraints on p.
2.2 Lattice constraints
We assume that the dose combination are ordered so that pij ≤ pi′j′ if i ≤ i′ and
j ≤ j′. These constraints define a partial order on the collection {pij, i = 1, . . . , I, j =
1, . . . , J} which is illustrated using a Hasse diagram in Figure 1.
Recall that p = (p11, p12, p13, . . . , pIJ) collect all the probabilities of DLT. The
partial ordering constraints on p can be encoded as the intersection of the following
sets:
Ω1 = Ω11 =
{
p | 0 < p11 < min(p12, p21)
}
,
...
Ωk = Ωij =
{
p | max(pi−1,j, pi,j−1) < pij < min(pi,j+1, pi+1,j)
}
, (5)
...
ΩK = ΩIJ =
{
p | max(pI−1J , pI,J−1) < pIJ < 1
}
.
where K = IJ . Note that we are using the bijection η : [I] × [J ] → [IJ ] given by
η(i, j) = (i− 1)J + j to transform a two-dimensional indexing to a one-dimensional
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index. For example, when J = 4 we have Ω5 = Ω2,1 and so on. We will use these
two indexings interchangeably throughout the paper. In particular, we often write
the elements of p in the one-dimensional index as well p = (p1, p2, . . . , pK).
The partial ordering constraints can be summarized as requiring
p ∈ Ω, where Ω :=
K⋂
k=1
Ωk ⊂ [0, 1]K .
In the sequel, we refer to Ω as the lattice. We note that there is redundancy in the
specification of Ωk’s in (5) in that the same constraint might be enforced by multiple
Ωk’s. This redundancy is helpful in deriving the Gibbs sampler of Section 3.2.
3 Nonparametric Bayesian model for dual agents
We start by specifying our prior on p and then discuss how we can sample from the
prior and the posterior.
3.1 Nonparametric prior
Perhaps the most basic nonparametric prior on p is the uniform distribution on Ω.
The uniform distribution on the lattice has density
fu(p) ∝ 1Ω(p), where 1Ω(p) =
K∏
k=1
1Ωk(p) (6)
is the indicator of the lattice. By the uniform distribution being nonparametric, we
mean that one is not assuming a specific functional form for pij based on a lower-
dimensional parameter. We can extend (6) to a model with more general marginals.
Assume that we want a prior on p that is obtained as follows: Draw the coordinates of
p independently with pij having density bij(pij), then truncate the joint distribution
of p to the set Ω. The density of this prior is given by
f(p) ∝ 1Ω(p)
∏
i,j
bij(pij). (7)
In this paper, we take bij(·) to be beta densities:
bij(pij) ∝ pαij−1ij (1− pij)βij−1. (8)
Note that we can write (7) as
f(p) ∝
K∏
k=1
1Ωk(p)
∏
i,j
bij(pij) (9)
which is a form suitable for Gibbs sampling since the lattice structure encodes local
relations between elements of p. Given the neighbors of a node in the lattice, its
distribution is independent of the rest of the variables. In other words, f(p) is a
graphical model (Koller and Friedman, 2009) with the undirected lattice diagram
serving as its independence graph. For future reference, we will make the following
definition:
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Definition 1. The lattice-restricted beta distribution with shape parameters α =
(αij) and β = (βij) is the multivariate distribution defined by (8) and (9). We refer
to αij + βij as the (effective) sample sizes of the distribution (ESS).
It is worth noting that the marginals of p under a lattice-restricted beta dis-
tribution are not beta distributions themselves, due to the restrictions imposed by
the lattice constraint. The notion of the sample size in Definition 1 is based on the
common practice of referring to α+β as the effective sample size of beta(α, β) distri-
bution. The rationale behind this naming is well-known from the posterior inference
in beta-binomial models; see also (15). In a simple beta(α, β), the effective sample
size α + β can directly control the variance of the distribution. For the multivariate
lattice-restricted beta, the relation between the sample sizes αij+βij and the variances
of the components of p are much more complicated. In fact, the lattice constraint
indirectly restricts how much αij + βij influences the variance, making it challenging
to design diffuse priors. In Section 3.4, we propose a simple discounting scheme to
work around this issue.
3.2 Gibbs sampler for the prior
It is easy to sample from the lattice-restricted distribution (9) using a Gibbs sampler.
The updates are as follows: Let us derive the updates for the Gibbs sampler:
f(p11 | p−11) ∝ b11(p11) · 1Ω11(p)
...
f(pij | p−ij) ∝ bij(pij) · 1Ωij(p) (10)
...
f(pIJ | p−IJ) ∝ bIJ(pIJ) · 1ΩIJ (p)
where p−ij is the vector p with pij removed (i.e., all variables are included except
pij). Note that although each pij also appears in some other constraint sets besides
Ωij, we do not need to include them in the above conditional calculation since those
constraints are also enforced by Ωij. In other words, there is some redundancy in the
condition of Ω1,Ω2 . . . ,ΩK that we have introduced to simplify deriving the Gibbs
sampler.
Each conditional distribution in (10) is a truncated beta distribution which is easy
to sample from, where the truncated beta density is defined as
T (x;α, β, a, b) ∝ xα−1(1− x)β−11{x ∈ (a, b)}. (11)
Using this notation, for example,
f(p11 | p−11) = T
(
p11; α11, β11, 0,min(p12, p21)
)
.
Thus, all these conditional distributions are easily derived and they are all truncated
beta distributions that can be simulated efficiently.
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3.3 Posterior
Given prior (9) and the likelihood in (4), we can readily obtain the posterior,
pi(p | z) ∝ L(z | p) f(p)
∝
∏
i,j
p
zij
ij (1− pij)nij−zij
K∏
k=1
1Ωk(p)
∏
i,j
bij(pij)
∝
∏
i,j
p
αij+zij−1
ij (1− pij)βij+nij−zij−1
K∏
k=1
1Ωk(p)
(12)
using (8). We note that the posterior is of the form
pi(p | z) ∝
∏
i,j
b′ij(pij)
K∏
k=1
1Ωk(p) (13)
where b′ij(·) is the density of beta distribution with parameters αij+zij and βij + nij − zij.
That is, posterior (13) is of the exact same form as (9), that is, a lattice-restricted
beta distribution, with updated parameters. Thus, the Gibbs sampler derived earlier
for the prior, works for the posterior as well, using the new beta parameters.
3.4 Discounting the prior
The relatively high-dimensional prior in (9) will have reduced variances for compo-
nents of p, relative to those, one would expect when the components are independent.
This is due to the restrictions imposed by the lattice constraints and is a challenging
aspect of specifying priors in high dimensions under many constraints on the coordi-
nates. We believe the difficulty is present as long as one insists on the coordinates
satisfying strict order constraints and is not an artifact of the particular choice of the
beta densities.
At the early stages of the trial, due to the data having a small sample size and the
prior having diminished variances (hence high concentration), the posterior inference
will be dominated by the prior. This can be mitigated by controlling the sample size
of the data relative to the (effective) sample size of the prior. To do so, we evaluate
a pseudo-posterior by raising the likelihood to power ω > 1 as follows:
pi(p | z) ∝
(∏
ij
p
zij
ij (1− pij)nij−zij
)ω∏
ij
p
αij−1
ij (1− pij)βij−11Ω(p)
=
∏
ij
p
ωzij+αij−1
i (1− pij)ω(nij−zij)+βij−11Ω(p).
(14)
The resulting pseudo-posterior is again an instance of a latticed-restricted beta dis-
tribution, as in Definition 1, with shape parameters ωz +α and ω(n− z) + β.
The idea of raising the likelihood to a power has been explored in the literature to
address model misspecification (Royall and Tsou, 2003; Gru¨nwald et al., 2017; Bissiri
et al., 2016) and to incorporate historical data in a Bayesian analysis (Ibrahim et al.,
2000). Using this idea to simulate diffuse priors from high-dimensional concentrated
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priors, as we intend here, is new to the best of our knowledge. It is a natural approach
for tuning the relative effects of the data and the prior on the posterior as the following
simple example illustrates.
Consider the simple univariate model where z | p ∼ Bin(n, p) and p ∼ beta(α, β).
The ω-reweighed pseudo-posterior is a beta distribution with parameters ωz+α and
ω(n− z) + β, whose mean is given by
E[p | z] = ωz + α
ωn+ α + β
=: λ
z
n
+ (1− λ) α
α + β
(15)
where λ = ωn/(ωn + α + β) ∈ (0, 1). (Note that in (15), α + β plays the same role
in the prior term as does the sample size n in the data-driven term.) That is, the
posterior mean is a weighted (in fact, convex) combination of the maximum likelihood
estimate z/n, which is solely based on data, and the prior mean, with weights that
are controlled by λ. Parameter ω allows us a degree of freedom beyond the sample
size n to control the effect of the prior, effectively tuning its overall variance. In
particular, the weight of the data relative to the prior is given by ρ := λ
1−λ =
nω
α+β
.
For a desired level of ρ, which can be thought of as a user-specified level of confidence
in the prior, we can solve for the appropriate ω as
ω =
ρ(α + β)
n
. (16)
By choosing ρ, one can calibrates the relative influence of the prior and data on
the posterior. When ρ = 1, the relative influence of the prior and the data are as given
by the traditional Bayesian approaches. For a more outcome-adaptive inference, one
sets ρ to be greater than 1.
A value of ρ > 1 is what we suggest for the high-dimensional prior we are using
(Definition 1). As discussed earlier, the lattice constraint causes any prior distribution
to have diminished variances. A choice of ρ > 1 deflates the effect of the prior, in effect
simulating a more diffuse overall prior (i.e., having larger variance). Empirically, we
have found that setting ρ = 2 significantly improves the performance. Thus, we
choose ω = 1 + 2
∑
ij(αij + βij)/
∑
ij nij as suggested by (16) and since we need
ω > 1.
3.5 Choosing the hyperparameters
Let mij be the effective sample size of the beta prior pij (Definition 1). To choose the
hyperparameters, we do a grid search over different choices of values for m11 and mIJ
with the the rest of mijs being equal to a value that is less than min(m11,mIJ). If the
dose space is too large, one can limit the search space even further and assume that
m11 = mIJ . The grid search is done by running our Gibbs sampler algorithm (10)
many times with all these different combination of hyperparameters. At the end, we
choose the hyperparameters that match our prior guess of the toxicity probabilities.
The details for hyperparameter selection can be found in the Appendix A.
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4 Trial Design
To limit the exposure of patients to toxic combinations and provide better posterior
estimation, we enroll more patients to the first two cohorts. For better exploration
of the dose space, following Tighiouart et al. (2017), we enroll patients to different
dose combinations in each cohort c > 1. However, rather than alternating each time
between the vertical and horizontal direction, we choose the direction randomly.
Thus, the design of a Phase I trial for two agents using the proposed NBCD
proceeds as follows:
(1) The first 4 patients in the first cohort receive the minimum dose combination
(dA1 , d
B
1 )
(2) In the second cohort, patients 5 and 6 receive (dA1 , d
B
j∗), where
j∗ = argmin
j
|pˆ1j − θ| (17)
Similarly, patient 7 and 8 receive (dAi∗ , d
B
1 ), where
i∗ = argmin
i
|pˆi1 − θ| (18)
(3) In the c-th cohort (c ≥ 3) of two patients, from each of the two dose combina-
tions in cohort c−1, choose between horizontal and vertical direction randomly
to fix one drug level and vary the other drug level and find the dose combination
with posterior median probability of DLT closest to θ similar to (17) and (18).
If the posterior median DLT probability of minimum dose of one direction or
both directions is greater than 1.5 × θ, choose the direction with the lowest
minimum one.
(4) Repeat step (3) and terminate the trial when all the patients are enrolled, or
the following stopping rule holds.
Stopping rule: Stop the trial after n patients are accrued if
P(pˆ(n)11 > θ + γ) >  (19)
where, γ and  are the stopping rules parameters.
4.1 Recommended phase II doses
At the end of the trial, we recommend one or more dose combinations to be used in
future phase II studies. To achieve this, we first set the margins δl and δu and consider
an asymmetric neighborhood N around θ, that is N = [θ− l, θ−u] ⊆ [θ− δl, θ− δu].
We start with small l and u and gradually increase them until for some (i, j), pˆij ∈
N . Among these dose levels, we recommend the ones that were experimented more
than once (If no dose levels are available as such, we recommend the ones that are
experimented once). If no dose levels belong to [θ − δl, θ − δu], then we do not
recommend any doses. Algorithm 1 summarizes the steps for recommending doses
for phase II.
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Algorithm 1 Dose recommendation for phase II
1: Set δl, δu, the step sizes γu, γl, ηu and pick initial values l0, u0.
2: Set I ← ∅; l← l0; u← u0
3: if
{∑
ij 1{pˆij>θ}
K
≥ 1
2
}
then
4: The scenario is toxic; Set toxic ← 1.
5: end if
6: while I = ∅ AND (l ≤ δl OR u ≤ δu) do
7: Update I ←
{
(i, j) : −l ≤ pˆij − θ ≤ u
}
8: Update l← l + 1{l ≤ δl} × γl
9: Update u← u+ 1{u ≤ δu}
(
ηu × toxic + γu × (1− toxic)
)
10: end while
11: Return M̂TD(δ) =
{
dij : (i, j) ∈ I, nij > 1
}
5 Simulations
In this section, we show the effectiveness of our proposed method in comparison with
the existing methods through various simulation studies. For all the following simu-
lations and the real trial design, we define the MTD(δ) as any dose combination that
is within δ = 0.1 of the the target probability and the MTD(δ) is estimated using Al-
gorithm 1. We also use δl = 0.1 and δu = 0.05, l0 = 0.05, u0 = 0, γl =
δl
2
, γu =
δu
2
and
ηu =
δu
5
, throughout. All the trials start from the lowest dose level d11 = (d
A
1 , d
B
1 ). We
use a cohort size of 4 for the first two cohorts and a cohort size of 2 for the rest. The
toxicity outcome is generated as a Bernoulli random variable that takes a value of 1
with probability pij and 0 from the corresponding scenario. For finding the median
posterior, we took 11000 posterior samples and discarded 1000 burn-in iterations in
Gibbs sampling procedure. To select the hyperparameters, we used a grid search
as explained in section 3.5. For each scenario, 2000 simulated trials are replicated
to evaluate the operating characteristics of NBCD and other methods. Specifically,
we calculated the mean percentage that each dose combination was selected as the
MTD(δ) at the end of the trial (recommendation percentage) and the mean percent-
age of patients assigned to each dose combination (experimentation percentage). For
PIPE design, the (weak) prior sample size of 1
I∗J was used as suggested by Mander
and Sweeting (2015). The dose escalation is done by a neighborhood constraint, with
admissible doses chosen from those closest to the estimated MTD contour.
5.1 Simulation Study I
For the first simulation study, we compare the performance of NBCD with the results
from Mander and Sweeting (2015) (previously examined by Braun and Jia (2013))
under scenarios A-G that are reproduced in Table 1. These methods include the
generalized CRM (gCRM) Braun and Jia (2013), the coupla model of Yin and Yuan
(2009a) and the latent contingency method by Yin and Yuan (2009b) and the product
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Table 1: Dose limiting toxicity for simulation study I
Drug A
1 2 3 4 1 2 3 4
Scenario A Scenario E
1 0.04 0.08 0.12 0.16 0.08 0.18 0.28 0.29
2 0.10 0.14 0.18 0.22 0.09 0.19 0.29 0.30
3 0.16 0.20 0.24 0.28 0.10 0.20 0.30 0.31
4 0.22 0.26 0.30 0.34 0.11 0.21 0.31 0.41
Scenario B Scenario F
1 0.02 0.04 0.06 0.08 0.12 0.13 0.14 0.15
2 0.05 0.07 0.09 0.11 0.16 0.18 0.20 0.22
3 0.08 0.10 0.12 0.14 0.44 0.45 0.46 0.47
4 0.11 0.13 0.15 0.17 0.50 0.52 0.54 0.55
D
ru
g
B
Scenario C Scenario G
1 0.10 0.20 0.30 0.40 0.01 0.02 0.03 0.04
2 0.25 0.35 0.45 0.55 0.04 0.10 0.15 0.20
3 0.40 0.50 0.60 0.70 0.06 0.15 0.30 0.45
4 0.55 0.65 0.75 0.85 0.10 0.30 0.50 0.80
Scenario D
1 0.44 0.48 0.52 0.56
2 0.50 0.54 0.58 0.62
3 0.56 0.60 0.64 0.68
4 0.62 0.66 0.70 0.74
of independent beta probabilities (PIPE) Mander and Sweeting (2015). Among all
these methods, PIPE and NBCD are nonparametric and the rest are parametric
models.
The target toxicity probability θ is set at 0.2 and the total sample size is 50. The
median prior for the probability of DLT at the smallest and largest dose combinations
is set to 0.04 and 0.34, respectively to match that of scenario A. The stopping rules
parameters γ = 0.1 and  = 0.8 are used.
The operating characteristics of the NBCD method and all the other methods
are shown in Table 2, where the results from the parametric models and the PIPE
method were produced from Table IV of Mander and Sweeting (2015). In scenario
D where all doses are toxic, all methods perform well in the sense that they do not
recommend an MTD. Our method outperforms all the other methods in scenarios
A,E,F in dosing at the target and in scenarios A,F,G in dose recommendation within
10% of the target. In particular, the percent recommendation within 10% of the
target for NBCD exceeds that of PIPE by an absolute 13% and 23% under scenarios
A and G, respectively. The percent of patients allocated to doses within 10% of the
target is higher for PIPE relative to NBCD under scenarios A, B, and E and they
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Table 2: Experimentation and recommendation percentages for simulation study I
Recommendation percentages Experimentation percentages
At θ 1-10% > 10% None At θ 1-10% > 10% None
Scenario Model of θ of θ of θ of θ
A gCRM 10 82 3 5 6 72 17 5
YY09a 13 82 5 0 13 72 15 0
YY09b 11 81 6 2 10 70 20 0
PIPE 10 88 3 0 8 87 5 0
NBCD 16 83 1 0 10 76 14 0
B gCRM 0 94 3 3 0 87 13 0
YY09a 0 99 1 0 0 86 14 0
YY09b 0 96 4 0 0 71 29 0
PIPE 0 83 17 0 0 82 18 0
NBCD 0 96 4 0 0 72 28 0
C gCRM 45 39 5 11 30 41 18 11
YY09a 41 50 5 4 27 54 16 3
YY09b 42 47 5 6 29 55 11 5
PIPE 29 59 7 5 19 46 34 2
NBCD 32 54 14 0 20 48 31 1
D gCRM 0 0 4 96 0 0 22 78
YY09a 0 0 1 99 0 0 20 80
YY09b 0 0 1 99 0 0 16 84
PIPE 0 0 1 99 0 0 37 63
NBCD 0 0 4 96 0 0 41 59
E gCRM 9 70 14 7 5 56 32 7
YY09a 6 65 27 2 9 55 34 2
YY09b 7 67 25 1 6 54 38 2
PIPE 11 84 4 1 9 77 13 1
NBCD 15 78 7 0 10 70 20 0
F gCRM 13 70 6 11 10 64 16 10
YY09a 14 76 6 4 7 75 14 4
YY09b 12 74 7 7 7 77 9 7
PIPE 12 75 11 2 12 69 18 2
NBCD 16 72 11 1 14 65 20 1
G gCRM 25 68 5 2 18 57 24 1
YY09a 12 76 12 0 3 71 26 0
YY09b 15 72 13 0 7 61 32 0
PIPE 9 62 29 0 14 54 31 0
NBCD 20 74 6 0 15 56 29 0
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Table 3: Dose limiting toxicity scenarios in simulation study II
Drug A
1 2 3 4 5 1 2 3 4 5
Scenario 1 Scenario 2
1 0.05 0.07 0.11 0.16 0.23 0.01 0.03 0.07 0.09 0.11
2 0.07 0.12 0.17 0.24 0.33 0.04 0.06 0.08 0.10 0.22
3 0.12 0.18 0.25 0.33 0.43 0.09 0.13 0.22 0.25 0.27
4 0.18 0.27 0.35 0.43 0.50 0.12 0.16 0.23 0.28 0.30
Scenario 3 Scenario 4
1 0.30 0.35 0.40 0.50 0.55 0.01 0.03 0.08 0.12 0.15
D
ru
g
B
2 0.40 0.55 0.65 0.75 0.85 0.02 0.05 0.10 0.16 0.30
3 0.50 0.60 0.70 0.80 0.90 0.07 0.09 0.15 0.25 0.35
4 0.55 0.70 0.75 0.85 0.95 0.10 0.26 0.30 0.33 0.50
Scenario 5 Scenario 6
1 0.07 0.12 0.20 0.25 0.30 0.10 0.15 0.20 0.30 0.45
2 0.10 0.18 0.23 0.30 0.35 0.11 0.20 0.30 0.40 0.50
3 0.30 0.48 0.56 0.65 0.68 0.15 0.30 0.35 0.50 0.60
4 0.40 0.55 0.60 0.66 0.70 0.30 0.40 0.50 0.60 0.65
Scenario 7
1 0.11 0.12 0.13 0.14 0.15
2 0.14 0.20 0.25 0.30 0.35
3 0.16 0.25 0.40 0.55 0.60
4 0.20 0.40 0.60 0.90 0.95
are fairly close for scenarios C, F, and G. Given that the primary goal of phase I
trials is estimation of the MTD, we conclude that our method is competitive with
the other approaches under the scenarios studied by Braun and Jia (2013); Mander
and Sweeting (2015).
5.2 Simulation Study II
For our second simulation study, we investigate the performance of our method un-
der an asymmetric dose-combination space with seven 4 by 5 scenarios, see Table
3. These scenarios cover a wide range of dose–response relationships and include
cases where the MTD is achieved at the highest dose combination (scenario 2), low-
est dose combination (scenario 3), and more complex structures (scenarios 5 and 7).
We compare our method with PIPE as it is a nonparametric model. The target
toxicity probability θ is set at 0.3 and the total sample size is 50 with a cohort size
of 2 for PIPE. For a fair comparison, we do not impose any early termination for
NBCD and PIPE. The median prior for the probability of DLTs at the smallest and
largest dose combinations was set to 0.05 and 0.50, respectively. We then chose the
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Table 4: Experimentation and recommendation percentages for simulation study II
Recommendation % Experimentation %
At θ 1-10% > 10% None At θ 1-10% > 10%
Scenario Model of θ of θ of θ of θ
1 NBCD 0.0 84.0 16.0 0.0 0.0 58.1 41.9
PIPE 0.0 75.0 25.0 0.0 0.0 60.9 39.1
2 NBCD 6.8 81.3 11.5 0.4 6.3 53.8 39.9
PIPE 4.2 64.3 31.5 0.0 5.5 56.8 37.7
3 NBCD 24.6 60.7 10.5 4.2 26.4 49.6 24.0
PIPE 24.0 40.5 35.4 0.1 19.4 33.3 47.3
4 NBCD 29.7 52.5 17.5 0.3 20.4 36.6 43.0
PIPE 25.4 38.4 36.2 0.0 19.4 32.4 48.2
5 NBCD 36.7 41.4 20.5 1.4 25.3 29.5 45.2
PIPE 36.5 39.6 23.6 0.3 22.3 29.3 48.4
6 NBCD 52.3 38.8 8.6 0.3 35.3 34.1 30.6
PIPE 40.7 35.9 23.0 0.4 30.7 36.9 32.4
7 NBCD 16.8 72.9 9.8 0.5 9.8 56.5 33.7
PIPE 10.0 60.6 29.4 0.0 10.2 52.9 36.9
hyperparameters that match our prior guess of the toxicity probabilities as discussed
in section 3.5. We used scenario 1 as the prior for both NBCD and PIPE. Table 4
shows that NBCD outperforms PIPE in all scenarios with respect to percent recom-
mendation within 10% of the target probability of DLT θ with the highest percent
equal to 20% achieved in scenarios 2 and 3. The percent of patients allocated to
doses within 10% of the target are fairly similar between the two methods except for
scenario 3 where NBCD allocates 23% more patients than PIPE. The safety profiles
of the two methods are presented in Table 5. In general, the average percent of DLTs
across all simulated trials are fairly close in all seven scenarios but PIPE tends to
allocate more patients to overtoxic doses and is more likely to recommend overtoxic
doses under scenarios 3 and 6. Finally, PIPE is more likely to result in a trial with
an excessive rate of DLTs relative to NBCD as assessed by the percent of trials with
a DLT rate more than θ + 0.1. In particular, the probability that a prospective trial
using PIPE will result in an excessive rate of DLTs under scenario 3 exceeds that
of NBCD by 32.4%. Based on these scenarios, we conclude that NBCD approach is
safer than PIPE and more efficient in recommending the MTD.
6 Trial Application
We used our approach NBCD to design a phase I trial of the combination Gemcitabine
(Gem) and CB-839, an orally bioavailable inhibitor of Glutamine in advanced stage
pancreatic cancer patients refractory to first-line FOLFIRINOX (5-Fluorouracil (5-
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Table 5: Trial safety evaluation for simulation study II
Design 1 2 3 4 5 6 7 Average
Recommendation % of overtoxic doses
NBCD 4.4 0.0* 9.7 0.3 12.4 5.3 1.3 5.6
PIPE 5.6 0.0* 22.4 0.0 10.5 13.7 2.8 9.2
Allocation % of patients to overtoxic doses
NBCD 6.0 0.0* 24.0 1.4 22.2 9.9 4.9 11.4
PIPE 8.7 0.0* 40.4 2.8 29.2 19.4 11.5 18.7
Average rate of DLTs
NBCD 23.3 18.4 39.6 20.8 30.2 29.3 26.7 26.9
PIPE 25.8 20.2 43.7 22.8 34.2 32.6 29.5 29.8
% of trials with DLT rate > θ + δ
NBCD 0.0 0.0 34.7 0.0 1.6 0.1 0.0 5.2
PIPE 0.1 0.0 67.1 0.0 9.7 4.4 1.1 11.8
* The average excludes the items with asterisk
Table 6: Dose limiting toxicity scenarios in real trial design
CB-839
400 600 800 400 600 800
Scenario 1 Scenario 2
800 0.05 0.10 0.20 0.05 0.20 0.33
1000 0.10 0.20 0.30 0.15 0.33 0.50
Scenario 3 Scenario 4
G
em 800 0.01 0.03 0.07 0.30 0.40 0.50
1000 0.03 0.07 0.10 0.40 0.55 0.65
Scenario 5
800 0.30 0.50 0.60
1000 0.54 0.58 0.65
FU), Leucovorin, Irinotecan, and Oxaliplatin) at our institution. We will explore
two dose levels of Gem 800 and 1000 mg/m2 and three dose levels of CB-839, 400,
600, and 800 mg BID for a total of 6 possible dose combinations and we plan to
enroll n = 36 patients to the trial. The target probability of DLT is set to θ = 0.33
and the median prior for the probability of DLTs at the smallest and largest dose
combinations were set to 0.05 and 0.30, respectively. These restrictions were achieved
after discussion with the clinician who used the fact that CB-839 was well tolerated
at the highest dose when combined with other cytotoxic drugs from previous phase
I/II trials. The stopping rules parameters γ = 0.1 and  = 0.8 were used. We
evaluated the performance of NBCD and PIPE by simulating 2000 trials under the
five scenarios shown in Table 6.
For PIPE, a cohort of size 2 was used. Scenario 1 is a case where the MTD is
achieved at dose combination 800 mg CB-839 and 1000 mg/m2 gemcitabine. In sce-
nario 2, there are two MTDs. Scenario 3 has no MTDs. Scenario 4 has three MTDs
15
Table 7: Experimentation and recommendation percentages for the real trial
Recommendation % Experimentation %
At θ 1-10% > 10% None At θ 1-10% > 10% None
Scenario Model of θ of θ of θ of θ
1 NBCD 0.0 66.8 27.8 5.4 0.0 51.4 48.6 0.0
PIPE 0.0 23.6 75.9 0.5 0.0 36.3 63.4 0.3
2 NBCD 70.4 0.0 25.7 3.9 45.6 0.0 54.4 0.0
PIPE 47.8 0.0 51.3 0.9 53.4 0.0 46.4 0.2
3 NBCD 0.0 0.0 16.8 83.2 0.0 0.0 100 0.0
PIPE 0.0 0.0 100 0.0 0.0 0.0 100 0.0
4 NBCD 0.0 81.6 6.3 12.1 0.0 76.5 16.4 7.1
PIPE 0.0 72.2 5.3 22.5 0.0 67.4 21.9 10.7
5 NBCD 0.0 53.2 23.8 23.0 0.0 40.8 52.3 6.9
PIPE 0.0 54.1 12.9 33.0 0.0 41.5 46.4 12.1
and in scenario 5, the MTD is achieved at the minimum dose combination. The oper-
ating characteristics are presented in Tables 7 and 8. The percent recommendation
within 10% of the target dose using our approach is significantly higher than that
of PIPE under scenarios 1, 2, and 4 and the two approaches are equivalent under
scenario 5. For Scenario 3, although the probability of DLT at the maximum dose
combination is only 0.1, PIPE always recommends a dose. However, NBCD does not
recommend any doses in 83.2% of the trials. Furthermore, NBCD is safer as assessed
by the percent of trials with an excessive rate of DLT under scenarios 4 and 5. Based
on the high percent recommendation and safety summary statistics, we conclude that
our approach achieves good operating characteristics under various scenarios for the
location of the MTD.
7 Concluding Remarks
In this paper, we considered a nonparametric Bayesian approach to dose finding for
combinations of drugs (NBCD) in phase I clinical trials. This approach does not
rely on a specific functional form of the dose-toxicity relationship and hence does not
suffer from lack of robustness under strong model misspecification seen in parametric
methods. Our model imposes the partial ordering constraints on the probabilities
of toxicities by truncating the independent beta distributions to the set of partial
orders. Using the fact that the conditional distributions of the probabilities of DLT
given the remaining risk of toxicities are truncated beta densities, features of the
joint posterior probability of DLT are easily estimated using the Gibbs sampler. This
is in contrast to PIPE where independent prior beta distributions are placed on the
space of dose combinations; the partial ordering constraint is only enforced on the
estimated maximum tolerated contours during the trial. In addition, there is more
borrowing of information across the dose combination space using NBCD relative to
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Table 8: Trial safety evaluation for the real trial
Design 1 2 3 4 5 Average
Recommendation % of overtoxic doses
NBCD 0.0 10.2 0.0* 6.3 23.8 13.4
PIPE 0.0 1.0 0.0* 5.3 12.9 6.4
Allocation % of patients to overtoxic doses
NBCD 0.0 22.3 0.0* 16.4 50.4 29.7
PIPE 0.0 8.9 0.0* 21.9 46.4 25.8
Average rate of DLTs
NBCD 21.8 30.3 7.9 36.4 39.0 27.1
PIPE 21.9 28.0 9.0 45.9 48.8 30.7
% of trials with DLT rate > θ + δ
NBCD 0.2 0.5 0.0 19.5 39.8 12.0
PIPE 0.2 0.3 0.0 32.6 49.5 16.5
* The average excludes the items with asterisk
PIPE due to the partial ordering constraint a priori.
Due to the complexity of the joint prior probability of DLT p, we selected a sub-
class of priors such that the hyperparameters (αij, βij) are all equal, except perhaps
for the minimum and maximum dose combinations. These hyperparameters are then
selected using a grid search algorithm described in Appendix A. In our simulation
studies and the trial example, we ask the clinician to specify prior median proba-
bilities of DLT at the minimum and maximum dose combinations and among all
hyperparameters that satisfy this constraint, we select the combination that maxi-
mizes the trace of the covariance matrix of the prior joint probability of DLT p. This
simplified sub-class of priors is not computationally intensive and performs well in
our simulations under a large class of scenarios including cases proposed by other au-
thors. In addition, it is practically appealing to clinicians since it is easier to specify
a priori probabilities of DLT at the minimum and maximum dose combination than
it is for all combinations.
Dose allocation to successive cohorts of patients follows a modified continual re-
assessment scheme. It allows for better exploration of the dose combination space,
resulting in high recommendation percentages relative to previous approaches. It
is an extension of the algorithms proposed in Tighiouart et al. (2017), Diniz et al.
(2017) and Jimenez et al. (2019) where escalation of the two drugs simultaneously is
not allowed but the drug to be escalated (or de-escalated) is selected randomly. We
have shown that NBCD has comparable operating characteristics with other para-
metric approaches (Simulation Study I that is based on scenarios studied by Braun
and Jia (2013)) and outperforms PIPE in most scenarios for Simulation Study I-II
and the real trial example both in terms of percent MTD recommendation and safety.
We are currently working on extending this nonparametric design in the setting of
phase I/II drug combination trials where a separate dose efficacy model is specified
for combinations of cytotoxic and biologic drugs. While the extension using two cyto-
toxic agents is straight forward, using one or more biologic drugs is more challenging
to model non-parametrically since efficacy may increase at low dose levels and then
plateau past a threshold contour.
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In conclusion, NBCD is a good alternative approach to parametric model based
designs when robustness to model misspecification is a concern and it still borrows in-
formation across the dose combination space owing to the partial ordering constraint
on the prior probabilities of DLT. It outperforms the nonparametric approach PIPE
in the simulation studies we presented and the real trial example. However, it is com-
putationally more intensive than PIPE but operating characteristics for prospective
studies can be carried out in a few hours. Computer R codes are available from the
authors upon request.
A Details for hyperparameter selection
We choose α and β vectors to have the following forms:
α =
[
m(1− t) l . . . l Ms ],
β =
[
mt u . . . u M(1− s) ].
That is, all the elements of α, except the first and last, are taken to be equal, and
similarly for β. The values m,M, s, t, l and u are determined by a grid search as
follows.
We vary t and s in a subinterval of (0, 1) away from the boundaries, e.g., (0.2, 0.5).
We choose u and l such that u+ l ≤ min(m,M). To reduce the size of the grid search,
we can fix one of u or l. For example, we can set u = min(m,M)/2 − l and let l
vary in the interval [0.2, 0.4] × min(m,M). The two parameters m and M are also
varied, independently, over an interval [min(α0, β0), α0 +β0] where α0 and β0 are some
heuristic prespecified values. For example, α0 +β0 roughly specify the overall sample
size of the prior. Below we will discuss a heuristic for choosing α0 and β0 that we
have found effective in practice.
The goal of the gird search is to find a combination of hyperparameters such
that the resulting prior satisfies some specified criteria for the median probability at
selected dose combinations. Let p˜ij be the prior median for the (i, j)-th does combi-
nation. Often the median for the smallest and largest dose combinations, i.e., p˜11 and
p˜IJ , are required to match certain values and we have a range for the intermediate
dose combinations. For example, the following is a possible set of criteria for a 4× 4
lattice:
{p˜ | p˜11 ≈ 0.04, p˜44 ≈ 0.34, p˜12 < 0.1}.
This set is often rewritten by setting a tolerance, say δ = 0.01,
{p˜ | |p˜11 − 0.04| < δ, |p˜44 − 0.34| < δ, p˜12 < 0.1}. (20)
For each combination of the hyperparameters (m,M, t, s, l), we run the Gibbs sampler
and estimate the corresponding median and variance for each variable pij. We then
choose the combination for which the estimated prior medians satisfy the criteria (20).
If there are multiple solutions, we choose the one that maximizes the total prior
variance:
∑
i,j var(pij).
The heuristic we follow for setting the range of m and M above is as follows: We
consider a sequence of i.i.d. random variables p′ij ∼ beta(α0, β0) for i = 1, . . . , I and
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j = 1, . . . , J . We then consider the extreme order statistics of this sequence, i.e., the
minimum and maximum of {p′ij}. It is easy to analytically solve for α0 and β0 such
that the median of the distributions of these two order statistics have specific values.
In particular, we solve these equations to match the desired median values p˜11 and
p˜IJ . The values α0 and β0 thus obtained provide a good heuristic to set the range
[min(α0, β0), α0 + β0] for the grid search on m and M . (In fact, we conjecture that
the distribution of the extreme order statistics of {p′ij} match those of the prior (9)
when αij = α0 and βij = β0 for all i and j.)
As an example, the set of criteria for in the simulation study I is:
{p˜ | |p˜11 − 0.04| < 0.01, |p˜44 − 0.34| < 0.01}.
We used nm = 15 grid points for each of m and M , nt = 10 points for each of t and
s, and nl = 3 points for l. The grid search resulted in 625 solutions that satisfied the
criteria. Out of these, we chose the one that maximizes the total variance (i.e., the
trace of the covariance matrix of p) leading to the following choice of hyperparameters:
α =
[
4.52 0.4 . . . 0.4 0.2
]
,
β =
[
0.74 2.23 . . . 2.23 13.77
]
.
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